Skip to content
ChickenStockChickenStock
ResearchFilings

AI English summary of an SEC filing — figures as filed

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals REGN

Regeneron said on January 26, 2024 that it appointed Senior Vice President, Controller Christopher Fenimore as Senior Vice President, Finance and Chief Financial Officer under a previously disclosed CFO succession plan. He will succeed Robert E. Landry, who is retiring.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Period of report Summary published (UTC)

Key points

AI summary
  1. Regeneron said on January 26, 2024 that it appointed Senior Vice President, Controller Christopher Fenimore as Senior Vice President, Finance and Chief Financial Officer under a previously disclosed CFO succession plan. He will succeed Robert E. Landry, who is retiring.

  2. The company said the appointments of Fenimore and Jason Pitofsky will take effect the day after it files its Form 10-K annual report for fiscal 2023 with the SEC. It expects that filing on February 5, 2024. Pitofsky will be appointed Vice President, Controller.

  3. Regeneron said it raised Fenimore’s 2024 base salary to $660,000 and granted him equity awards with a target grant date fair value of $5,000,000 on December 2023. The awards consist of options to purchase 8,499 shares and 2,370 shares of restricted Common Stock.

  4. The company said Fenimore, 53, has served as Senior Vice President, Controller since January 2021 and began his career as an auditor at KPMG before joining the company in 2003. Pitofsky, 46, has served as Vice President, Accounting and Financial Reporting since January 2021 and joined the company in 2011.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Christopher Fenimore Named Chief Financial Officer

Regeneron said on January 26, 2024 that it appointed Senior Vice President, Controller Christopher Fenimore as Senior Vice President, Finance and Chief Financial Officer under a previously disclosed CFO succession plan. He will succeed Robert E. Landry, who is retiring.

Source · Based on the filing body and exhibits

Effective Date of CFO and Controller Appointments

The company said the appointments of Fenimore and Jason Pitofsky will take effect the day after it files its Form 10-K annual report for fiscal 2023 with the SEC. It expects that filing on February 5, 2024. Pitofsky will be appointed Vice President, Controller.

Source · Based on the filing body and exhibits

Fenimore Compensation Change and Equity Award

Regeneron said it raised Fenimore’s 2024 base salary to $660,000 and granted him equity awards with a target grant date fair value of $5,000,000 on December 2023. The awards consist of options to purchase 8,499 shares and 2,370 shares of restricted Common Stock.

Source · Based on the filing body and exhibits

Backgrounds of Newly Appointed Executives

The company said Fenimore, 53, has served as Senior Vice President, Controller since January 2021 and began his career as an auditor at KPMG before joining the company in 2003. Pitofsky, 46, has served as Vice President, Accounting and Financial Reporting since January 2021 and joined the company in 2011.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.